Literature DB >> 26788689

More than valve repair: Effect of cone reconstruction on right ventricular geometry and function in patients with Ebstein anomaly.

Xiao Li1, Si-Meng Wang2, Christian Schreiber3, Wei Cheng2, Ke Lin1, Jia-Yu Sun2, Dan Yang2, Shu-Hua Luo1, Qi An1, Yu-Cheng Chen4.   

Abstract

BACKGROUND: Cone reconstruction is a novel surgical procedure for tricuspid valve repair in Ebstein anomaly. This study examined the effect of cone reconstruction on right ventricle (RV) geometry, function, and synchronization.
METHODS: Twenty-one patients (4-49 year-old) underwent cone reconstruction were enrolled, and matched with healthy individuals. Pre-operative and follow-up echocardiography was performed along with cardiac magnetic resonance (CMR) imaging in 18 patients. A new parameter, tricuspid annular movement synchronicity index (TAMSI), was used to describe global synchronization of RV in the annular plane. TAMSI was defined as standard deviation of the systolic excursion of the hinge points of the three leaflets divided by their average value.
RESULTS: After 9.1 (range 1-12) months follow-up, there were no deaths; tricuspid regurgitation was reduced from moderate/severe to mild or less in 95.2% of patients. In 18 patients with both pre and post CMR data, functional RV volume decreased after repair (134.3 ± 58.3 ml/m(2) to 96.6 ± 29.6 ml/m(2); P=0.001), while ejection fraction was not significantly altered (38.2 ± 9.2% to 36.5 ± 8.5%; P=0.357). TAMSI was significantly reduced after surgery, from 0.613 ± 0.220 to 0.169 ± 0.088 (P<0.001). A value similar to the normal control (0.181 ± 0.081) indicated more synchronized RV movement pattern.
CONCLUSIONS: Cone reconstruction yielded good short-term survival in Ebstein anomaly. It reduced functional RV volume, improved RV global synchronization, and restored RV geometry. As such, it may improve RV performance and long-term prognosis. In addition, our described TAMSI proved to be a useful adjunct to postoperative assessments.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cardiac magnetic resonance (CMR); Cone reconstruction; Ebstein anomaly; Right ventricle; Tricuspid annular movement synchronicity index (TAMSI)

Mesh:

Year:  2016        PMID: 26788689     DOI: 10.1016/j.ijcard.2016.01.032

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  5 in total

Review 1.  Commentary: Predictors of postoperative adverse events after cone reconstruction for Ebstein's anomaly.

Authors:  Evan P Rotar; Irving L Kron
Journal:  J Card Surg       Date:  2021-01-27       Impact factor: 1.620

2.  Impact of the cone operation on left ventricular size, function, and dyssynchrony in Ebstein anomaly: a cardiovascular magnetic resonance study.

Authors:  Rebecca S Beroukhim; Linyuan Jing; David M Harrild; Brandon K Fornwalt; Abba Mejia-Spiegeler; Jonathan Rhodes; Sitaram Emani; Andrew J Powell
Journal:  J Cardiovasc Magn Reson       Date:  2018-05-21       Impact factor: 5.364

3.  Early and Long-Term Outcomes of Surgical Treatment of Ebstein's Anomaly.

Authors:  Guilherme Viotto Rodrigues da Silva; Leonardo Augusto Miana; Luiz Fernando Caneo; Aída Luiza Ribeiro Turquetto; Carla Tanamati; Juliano G Penha; Fabio B Jatene; Marcelo B Jatene
Journal:  Braz J Cardiovasc Surg       Date:  2019-12-01

Review 4.  SCMR Position Paper (2020) on clinical indications for cardiovascular magnetic resonance.

Authors:  Tim Leiner; Jan Bogaert; Matthias G Friedrich; Raad Mohiaddin; Vivek Muthurangu; Saul Myerson; Andrew J Powell; Subha V Raman; Dudley J Pennell
Journal:  J Cardiovasc Magn Reson       Date:  2020-11-09       Impact factor: 5.364

5.  Cardiovascular magnetic resonance evidence of myocardial fibrosis and its clinical significance in adolescent and adult patients with Ebstein's anomaly.

Authors:  Dan Yang; Xiao Li; Jia-Yu Sun; Wei Cheng; Andreas Greiser; Tian-Jing Zhang; Hong Liu; Ke Wan; Yong Luo; Qi An; Yiu-Cho Chung; Yuchi Han; Yu-Cheng Chen
Journal:  J Cardiovasc Magn Reson       Date:  2018-09-27       Impact factor: 5.364

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.